

# # 6

Page 1 of 1

FORM PTO-1449(Modified)		ATTY. DOCKET NO.: C1040/7006	SERIAL NO.: 09/316,199
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		APPLICANT: McCluskie et al.	
		FILING DATE: May 21, 1999	GROUP: 1614

## FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No
	B1	PCT/US99/11359		Search Report			

## OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

✓	C1	/	Lipford, G., et al., "CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants", <i>Eur. J. Immunol.</i> , (1997), 27:2340-2344				
✓	C2	/	McCluskie, M., et al., "CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen", <i>J of Immunol.</i> , (1999), 1:162:5:3103				
✓	C3	/	Liu, H., et al., "Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor", <i>BLOOD</i> , (1998), 92:10:3730-3736				
✓	C4	/	Klinman, D., et al., CpG motifs as immune adjuvants" <i>Vaccine</i> , GB, Butterworth Scientific Guildford, 17:1:19-25				

EXAMINER		DATE CONSIDERED	6/11/01
----------	---	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

FORM PTO-1449(Modified)			ATTY. DOCKET NO.: C1040/7006	SERIAL NO.: 09/316,199
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT			APPLICANT: McCluskie et al.	
			FILING DATE: May 21, 1999	GROUP: 1614

## OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

1	C1	/	DeLong, R. et al., "Characterization of Complexes of Oligonucleotides with Polyamidoamine Starburst Dendrimers and Effects on Intracellular Delivery", Journal of Pharmaceutical Sciences, Vol. 86, No. 6, June, 1997
	C2	/	Snider, D.P., "The Mucosal Adjuvant Activities of ADP-Ribosylating Bacterial Enterotoxins", Critical Reviews in Immunology 15(3&4):317-348 (1995)
	C3	/	Staats, H.F. et al., "Mucosal immunity to infection with implications for vaccine development", Current Opinion in Immunology 1994, 6:572-583
	C4	/	O'Hagan, D.T., Ph.D., "Novel Delivery Systems for Oral Vaccines", 1994, pp. 1-24
	C5	/	Lamm, M.E. et al., "Mechanism of IgA-Mediated Mucosal Defense", Vaccine Research, Vol. 1, Number 3, 1992, pp. 169-173
	C6	/	Constant, S.L. et al., "Induction of TH1 and TH2 CD4+ T Cell Responses: The Alternative Approaches, Annu. Rev. Immunol. 1997, 15:297-322, 1997
	C7	/	Bowersock, T.L. et al., "Evaluation of an orally administered vaccine, using hydrogels containing bacterial exotoxins Of Pasteurella haemolytica, in cattle", Am. J. Vet. Res., Vol. 55, No. 4, April 1994, pp. 502-509
	C8	/	Hogg, J.C., "The Pathology of Asthma", APMIS 105: 735-745, 1997
	C9	/	Gregoriadis, G., "Engineering liposomes for drug delivery: progress and problems", TIBTECH December 1995 (vol. 13), pp. 527-537
	C10	/	Sjolander, A. et al., "Kinetics, Localization and Isotype Profile of Antibody Responses to Immune Stimulating Complexes (Iscoms) Containing Human Influenza Virus Envelope Glycoproteins", Scand. J. Immunol. 43, 164-172, 1996
	C11	/	Douce, G. et al., "Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants", Proc. Natl. Acad. Sci. USA Vol. 92, pp. 1644-1648, February 1995 Immunology
	C12	/	Pizza, M. et al., "A Genetically Detoxified Derivative of Heat -Labile Escherichia coli Enterotoxin Induces Neutralizing Antibodies against the A Subunit", J. Exp. Med. Vol. 180, December 1994, pp. 2147-2153
	C13	/	Alpar Oya, H. et al., "Potential of Particulate Carriers for the Mucosal Delivery of DNA Vaccines", Biochemical Society Transactions (1997), 25, 337S
	C14	/	Holmgren, J. et al., "Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems"
	C15	/	O'Hagan, D.T. et al., "Controlled release microparticles for oral immunization", International Journal of Pharmaceutics, 108 (1994) 133-139
2	C16	/	Haneberg, B. et al., "Induction of Specific Immunoglobulin A in the Small Intestine, Colon-Rectum, and Vagina Measured by a New Method for Collection of Secretions from Local Mucosal Surfaces", Infection and Immunity, Jan. 1994, p. 15-23, pp. 1589-1595, 1995

DAW 6/14/01

PM	C17	/	Tokunaga, T. et al., "Antitumor Activity of Deoxyribonucleic Acid Fraction From Mycobacterium bovis BCG. I. Isolation, Physicochemical Characterization, and Antitumor Activity", Jnci. Vol. 72, No. 4, April 1984, pp. 955-962
	C18	/	Rappuoli, R. et al., "Genetic Detoxification of Bacterial Toxins: A New Approach to Vaccine Development", In Arch Allergy Immunol. 1995; 108:327-333
	C19	/	DeHaan, L. et al., "Mutants of the Escherichia coli Heat-Labile Enterotoxin with Reduced ADP-Ribosylation Activity or No Activity Retain the Immunogenic Properties of the Native Holotoxin", Infection and Immunity, Dec. 1996, p. 5413-5416
	C20	/	Kay, A.B., "TH2-Type Cytokines in Asthma", Allergy and Clinical Immunology, 1-8
	C21	/	Spangler, B.D., "Structure and Function of Cholera Toxin and the Related Escherichia coli Heat-Labile Enterotoxin", Microbiological Reviews, Dec. 1992, p. 622-647, Vol. 56, No. 4
	C22	/	Eldridge, J.H. et al., "Biodegradable Microspheres as a Vaccine Delivery System", Molecular Immunology, Vol. 28, No. 3, pp. 287-294, 1991
	C23	/	Lycke, N. et al., "The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity", Eur. J. Immunol. 1992, 22:2277-2281
	C24	/	Hornquist, E. et al., "Cholera toxin adjuvant greatly promotes antigen priming of T cells", Eur. J. Immunol. 1993, 23:2136-2143
	C25	/	Tsuji, T. et al., "Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus-1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen", Eur. J. Immunol. 1997, 27:782-787
	C26	/	Vadolas, J. et al., "Intranasal Immunization with liposomes induces strong mucosal immune responses in mice", Eur. J. Immunol. 1995, 25: 969-975
	C27	/	Maloy, K.J. et al., "Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS", Eur. J. Immunol. 1995, 25: 2835-2841
	C28	/	Sjolander, A. et al., "Iscoms Containing Purified Quillaja Saponins Upregulate both Th1-like and Th2-like Immune Responses", Cellular Immunology 177, 69-76 (1997) Article No. CI971088
	C29	/	Kukowska-Latallo, J.F. et al., "Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers", Proc. Natl. Sci. USA, Vol. 93, pp. 4897-4902, May 1996, Genetics
	C30	/	Schirmbeck, R. et al., "Immunization with Soluble Hepatitis B Virus Surface Protein Elicits Murine H-2 Class I-Restricted CD8+ Cytotoxic T Lymphocyte Responses In Vivo", Journal of Immunology, 1994, 152: 1110
	C31	/	Bird, A.P. et al., "CpG islands as gene markers in the vertebrate nucleus", TIG - December 1987, Vol. 3, no. 12 pp. 342-347
	C32	/	Davis, H.L. et al., "CpG DNA Is a Potent Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B Surface Antigen", The Journal of Immunology, 1998, 160: 870-876
	C33		Mestecky, J. et al., "Prospects for Human Mucosal Vaccines", 1992, 13-23
	C34	/	McGhee, J., et al., "The mucosal immune system: from fundamental concepts to vaccine development", Vaccine, 1992, 10:2:75-88,
	C35	/	Gallichan, W., et al., "Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus, 1995, 13:16:1589-1595

EXAMINER

JW

DATE CONSIDERED

6/17/01